



# HONG SENG CONSOLIDATED Marches Ahead

The unprecedented COVID-19 pandemic has disrupted all countries and appears to be gaining traction. The solution or end to this global crisis does not seem near. Therefore, as the COVID-19 crisis multiplies, the goal of businesses must be to rebuild and plan for the longer term.

With that in mind, Hong Seng Consolidated Berhad ("Hong Seng") or formerly known as MSCM Holdings Berhad has recently entered and ventured into a series of strategic partnerships and corporate exercises to form a future whereby Hong Seng

would emerge stronger from the crisis as Albert Einstein's famous sayings goes "in the midst of every crisis, lies great opportunity".

By planning for the current pandemic, Hong Seng has significant plans to transform its business into three (3) main pillars which include gloves manufacturing, healthcare and medical supplies and services and the hire purchase services which are in high demand now and the foreseeable future.

Subsequent to the emergence of Hong Seng Assembly Sdn Bhd (HSASB) as the new major

shareholder of the Group, Hong Seng had on 19th October 2020 announced its proposed diversification into the relevant businesses as mentioned above and we are on track with our plans to evolve and grow the Group by reducing reliance on our existing core business of search, advertising and data.

We believe that currently, Hong Seng will the only listed Group involved in or undertaking comprehensive end-to-end healthcare.

(eMedAsia), which runs a medical digital platform that caters to thousands of private clinics in the nation to be latter's service provider for healthcare supply chain management services particularly the 3PL and 4PL fulfilments which includes warehousing, process, pick & pack, last mile delivery and purchase of medical and healthcare products. It is a milestone for HS Bio as it shows its seriousness and capabilities to penetrate the above listed markets as MMA is an official body for medical practitioners and clinics.

The strategic partnership between HS Bio and eMedAsia is part of a novel medical initiative to revolutionise the private healthcare sector. This may be a solution to the estimated USD 3.5 billion valued medical tourism industry in Malaysia by 2024 according to an insight by Malaysia Healthcare Travel Council.




Besides that, HS Bio is also currently in talks with several leading healthcare and pharmaceutical companies in China to be their distributor in Malaysia and the region. We are in the midst of helping these Chinese companies to get their products registered and approved by the relevant local authorities. The said products include amongst others, supplements which had been empirically proven to be effective in boosting immunity against SARS and Covid-19 and is much sought after globally at the moment, and real-time PCR Test Kits for detection of Covid-19 which was tested and used in Malaysia at the start of the Movement Control Order back in March 2020.

Once these are registered and approved, Hong Seng aims to make Covid-19 testing very efficient, affordable and accessible via our network of clinics within the eMedAsia community since it is possible that hotspots will require testing to be done before employees are allowed back to work. Again, our efforts will supplement and complement our government's efforts and strategy to combat the current wave.

Pursuant to positive discussions, HS Bio has also been invited to submit letters of intent to be the distributor of China developed vaccines to three (3) separate China parties. To undertake this endeavor of distributing the Covid-19 vaccines in Malaysia, we have tied up with one of the oldest and most established local pharmaceutical company, Royce Pharma through a consortium agreement. We would like to highlight to our shareholders and investors that to be accredited and licensed as a pharmaceutical company in Malaysia entails stringent steps such as lengthy regulatory applications. Further, to deal in vaccines, a distributor has to be properly equipped with the necessary infrastructure such as cold room warehousing, handling facilities and knowledge. These need time to construct and thereafter, be audited by the relevant innovators or manufacturers.

Therefore, a tie-up like our consortium agreement with Royce Pharma is the most practical and realistic approach compared to other non-pharmaceutical licensed companies claiming to distribute Covid-19 vaccines. This is also because Royce Pharma is able to carry out fill and finish processes required. In due course, we envision testing and vaccination to take place in private clinics for maximum reach and penetration and we will be best positioned to support our nation. We truly understand efforts by our Malaysian government in its participation in COVAX, which is costly yet unable to cover 100% of the Malaysian population and residents and this is where Hong Seng will be able to support our nation in her fight against Covid-19.



This is the reason why we believe we are at the forefront at this point of time as we have also written in to the relevant government ministry to indicate our readiness to support all governmental efforts to vaccinate our population once the vaccines are available.


Moreover, we are working closely with our strategic partner, Line Clear Express & Logistics Sdn Bhd to boost our supply chain management capability in providing 3PL and 4PL services to support our businesses such as eMedAsia's collaboration which includes mobile testing and vaccination trucks, glove fulfilment, vaccines and also other significant health products and services. All of these are just a small part of our vision to empower our nation in the fight against the pandemic.

Hong Seng is working very hard to delve into the healthcare sector and serve our nation. Our latest development is to be involved in supplying PCR Test Kits to government agencies especially to assist in the ongoing outbreak in Sabah. Discussions are also taking place to assist in building additional Test Labs for processing samples from the mass Covid-19 screenings. Hong Seng will make the relevant announcements when these come into fruition.

## Eyeing on USD18.8 Billion (And Growing) Global Glove Market

Based on the US-based Allied Market Research's report which estimated that the global disposable gloves market is expected to nearly triple to US\$18.8 billion by 2027, Hong Seng has set its eyes on the opportunity from single-use medical gloves that have become increasingly difficult and costly to come by during this health crisis.

At the end of August 2020, Hong Seng through its wholly-owned subsidiary, Hong Seng Gloves Sdn Bhd (Hong Seng Gloves) has appointed its turnkey partner, Howellcare Industries Sdn Bhd to commission six (6) units of Nitrile Rubber (NBR) double former glove dipping production lines with utilities support system for our factory site located at Sungai Petani, Kedah.



Whilst we are currently ahead of schedule, the expected production capacity and output for each of the NBR double former glove dipping production line

is 241,920,000 pieces per annum whilst the total expected production capacity and output for all 6 units of the NBR double former glove dipping production lines is 1,451,520,000 pieces per annum. Hong Seng Gloves plans to increase up to a total of 16 production lines by early 2023 subjected to obtaining all necessary approvals to produce up to 3,870,720,000 pieces per annum as demand and preorder requests from countries who are unable to procure from big players have been overwhelming.



Furthermore, Hong Seng Gloves have also secured its supply of raw material for NBR gloves and our total cost is estimated about USD24.00 to USD25.00 per carton of 1,000 pieces while the current average selling price is around USD90.00 per carton.

Shareholders or any interested parties who wants to keep abreast with the latest progress of the glove manufacturing plant may do so on our Group's website at [www.hongseng.com.my](http://www.hongseng.com.my).



## Empowering Malaysians In The Fight Against Communicable Diseases And Beyond

Health is wealth. According to an online article published on the National Center for Biotechnology Information of United States titled "Learning opportunities from COVID-19 and future effects on health care system", the authors concluded that crisis like COVID-19 pandemic has also offered some unique opportunities for the healthcare sector. It has allowed us to revisit our healthcare delivery. Although, there has been severe disruption in healthcare delivery during this time globally, several positives have also come out of which include the effective use of telemedicine, importance of personal hygiene, and the importance of infection control.

Thus, Hong Seng intends to go full steam ahead in the healthcare industry and be at the forefront of the

Malaysian healthcare sector. Its wholly-owned subsidiary, HS Bio Supplies Sdn Bhd (HS Bio) is engaged in the business to provide pharmaceutical, medical and healthcare supplies such as e-medicine, medical consumables, bio supplies, medical equipment or devices, test-kits, vaccines, supplements, and other medical and healthcare related products as well as healthcare related services such as mobile testing facilities in addition to the supply chain management services for the healthcare industry.

The Group believes that HS Bio has promising prospects in the healthcare industry due to various factors. On 28th August 2020, HS Bio has invested and partnered with the Malaysian Medical Association (MMA) linked eMedAsia Sdn Bhd



## Filling Up The Vital Vacuum In The Financing Sector

Although the government has poured in hundred of billions in subsidies to help the people, however there are still many people and businesses who are greatly affected by the pandemic. Therefore, in July 2020, our Group has ventured into the hire purchase and related business through our wholly-owned subsidiary, HS Priority Management Sdn Bhd (HS Priority) to complement our Group's existing moneylending business with focus on extending our hire purchase facilities for commercial vehicles as well as industrial machineries and equipment.

The pervasiveness of the e-commerce landscape in Malaysia, in particular after the MCO implemented by the Malaysian government, has led to flourishing demand for logistics services in particular the last-mile delivery. This has generated growth for those who supply vehicles to last-mile delivery service providers as well as demand for loans to automotive for commercial vehicles.

Many industry players such as logistics, shipping ports and yards, mining, manufacturing and many others are facing issues in their cash flows but there is a need and opportunity during this tough time to expand their vehicle fleet and production capacity to meet the surging demands and HS Priority is here help ease their burden to own the much needed vehicles and heavy machineries such as lorries, trucks, cranes, forklifts and etc.



At the moment, due to cashflow impact, many borrowers may not have access to the types of loan facilities made available by licensed banks and other financial institutions due to stringent lending requirements imposed.

Hence, we believe that HS Priority will be able to help fill the vital vacuum which exists in the current financing sector as we aims to provide financial support to all industries by providing our customers with flexible financing schemes and competitive interest rates.

## OUR VISION

With the above initiatives, Hong Seng believes that our Group will be able to create a good sustainable future together with our stakeholders. As we are committed to be a good corporate citizen, we are working hard to support the nation in our own capacity by not just focusing on a single segment of healthcare to make profits but end-to-end healthcare for maximum efficiency.

At Hong Seng, we take aim to not to only to deliver commercial objectives and meet legal requirements, but also have a positive social impact on our community and those communities of our customers.



**HONG SENG CONSOLIDATED BERHAD**  
(Formerly known as MSCM Holdings Berhad)  
[www.hongseng.com.my](http://www.hongseng.com.my)



# 丰盛综合· 坚挺前进

2019冠状病毒病（COVID-19）大流行席卷全球，带来前所未有的破坏性，而且疫情看似再度升温，这场全球危机似乎还未见到解决方案或走到尽头的迹象。随着这场冠病危机加剧，企业必须要重设目标，为长期做好规划。

爱因斯坦说：“在每一次的危机之中，都蕴藏着巨大的机会”，为此，丰盛综合有限公司（Hong Seng Consolidated Berhad，前称为MSCM控股有限公司）近期进行了一系列

战略联盟和企业活动，确保能在此次危机中变得更强大，以迎接未来。

为了应对当前的大流行病，丰盛制定了重大的转型计划，迈向三大业务支柱，包括手套生产、医疗保健和医疗用品供应与服务，以及租购融资服务，皆是现在和未来的高需求领域。


随着丰盛组装机私人有限公司崛起成为集团大股东后，丰盛在2020年10月19日公布业务多元化献议，进军上述提及的相关行业。我们正按计划进行改革和壮大业务，以降低对当前搜寻、广告和数据核心业务的依赖。

我们相信，丰盛目前是参与或开展全面端到端医疗保健业务的上市公司。

## 放眼全球至少188亿美元的手套市场

根据美国Allied Market研究公司的报告，估计全球一次性手套市场将在2027年时增长近3倍，达**188亿美元**，丰盛将目光锁定在一次性医用手套的商机，尤其是在这次的健康危机中，医用手套越来越难获取且昂贵。

截至2020年8月，丰盛通过独资子公司——丰盛手套私人有限公司，委任统包伙伴Howellcare Industries私人有限公司，利用我们在吉打双溪大年厂房的公用事业系统，支撑6条丁腈手套双模手套浸渍生产线投入运作。



我们目前比原定进度超前，预计每条丁腈手套双模手套浸渍生产线的年度产量为**2亿4192万只**，全6条丁腈手套双模手套浸渍生产线的总产量为每年**14亿5152万只**。由于各国的需求和预购请求过多，大型业者也无法承接，丰盛手套计划在2023年初时将生产线增加至16条，每年可生产高达**38亿7072万只**。（须经所有单位批准）。

再者，丰盛手套还确保了定睛手套原料的供应，每箱1000只手套的总成本预计约**24美元至25美元**，而当前的平均销售价为每箱约**90美元**。

有意了解手套厂房最新进度的股东或任何人士，皆可浏览我们集团官网[www.hongseng.com.my](http://www.hongseng.com.my)

## 助国人更强地对抗传染病

健康就是财富。根据发表于美国国家生物技术信息中心的《冠病带来的学习机会和对未来卫生保健系统的影响》线上文章，作者总结认为，如冠病大流行这般的危机，为医疗保健领域提供了独特的机会，让我们重新审视医疗保健的服务机制。虽然在这段期间，全球的医疗保健服务领域遭严重破坏，但同时激发出不少正面且积极的意识，包括有效使用远程医疗、个人卫生和感染控制的重要性。



因此，丰盛打算在医疗保健行业中全力以赴，站在马来西亚医疗保健领域的最前线。其独资子公司HS Bio Supplies私人有限公司从事制药、医用和医疗保健供应，包括电子医疗、医疗耗材、生物用品、医疗设备或装置、测试套件、疫苗、补品、其他医用和医疗保健相关产品，还有包括移动测试设备的医疗保健相关服务，为医疗保健领域的供应链管理服务尽一份力。

本集团有信心，HS Bio可借着各项优势在医疗保健领域茁壮发展。在2020年8月28日，HS Bio投资了与马来西亚医疗协会（MMA）相关的eMedAsia私人有限公司，并携手展开合作。后者所营运的医疗数字平台，服务着国内数千家的私人诊所。HS Bio将作为eMedAsia的医疗保健供应链管理服务商，特别是在第三方和第四方物流服务，包括仓储、处理、提货和包装、最后一公里交付，以及购买医疗和医疗保健领域产品。能和作为执业医师和诊所官方机构的MMA合作，是HS Bio一项重大的里程碑，展现了其进军上述市场的认真和能力。

HS Bio和eMedAsia的战略合作，可说是私人医疗保健领域的一项新颖革新之举，或许更是医疗保健旅游市场的解决方案之一。根据马来西亚医疗保健旅游委员会，该市场在2024年时估计价值**35亿美元**。


除此之外，HS Bio目前和数家中国领先的医疗保健和制药企业洽商，冀望成为其在马来西亚和区域内的分销商。我们正在帮助这些中企获得产品的注册和相关当局的批准，产品包括经证明能针对非典型肺炎（SARS）和冠病加强免疫力、且当前在全球获得青睐的补品；还有用于检测冠病的即时聚合酶链式反应（PCR）测试盒，自2020年3月施行行动管制令以来已在马来西亚开始测试和采用。

由于冠病热点地区的雇员在返回办公岗位前或需要进行冠病测试，一旦上述产品获得注册和批准，丰盛放眼通过MedAsia的诊所网络，提供更有效、可负担和方便的冠病测试，致力辅助政府对抗当前的疫情。

经过积极的讨论后，HS Bio也受邀呈交意向书予三家不同的中国单位，以期成为中国所研发疫苗的分销商。为了也

在马来西亚分销冠病疫苗，我们和本地其中一家历史最悠久的知名制药公司Royce Pharma签署了财团协议。我们想向股东和投资者强调，要在马来西亚获得制药公司的认证和执照，需要经过严格的程序和冗长的监管申请。此外，欲分销疫苗的企业也必须具备适当的知识和基础建设，如冷藏仓储和处理设施，而这些都是需要时间准备和兴建，且需要经过相关的创造或生产商审核。

因此，相较于其他未持有制药执照却声称能分销冠病疫苗的公司，我们和Royce Pharma的财团协议合作方式，显得更加实用和实际。这亦是因为Royce Pharma有能力进行所需的装瓶程序。在适当的时候，我们放眼在私人诊所进行测试和疫苗接种，最大程度覆盖和触及国人，成为国人的后盾。我们完全了解马来西亚政府参与“全球冠病疫苗机制”（COVAX）所做出的努力，成本高昂却无法全面覆盖马来西亚所有人口和居民，而这恰是丰盛能帮助国家对抗冠病的地方。



这正是为何我们认为丰盛要领跑在最前线的原因，我们已向相关政府部门发出信函，承诺一旦疫苗到位，愿意全力支持政府为国人接种疫苗的一切努力。

再者，我们同时和战略伙伴Line Clear Express & Logistics私人有限公司紧密合作，加强我们的供应链管理，确保能支援旗下业务的第三方和第四方物流服务，比如说和eMedAsia的合作、流动测试和疫苗车、手套交付、疫苗和其他重大医疗保健产品和服务。上述所提及的，仅是我们盼望帮助国家抗击大流行病的一小部分努力。

丰盛正致力于深入于医疗保健领域以为国人服务，最新发展是参与供应PCR测试盒予政府机构，尤其能在沙巴持续爆发的疫情中助一臂之力。我们也讨论帮助兴建更多的测试实验室，以处理大规模的冠病筛选样本。待有进一步的发展，丰盛会适时作出宣布。

## 填补融资领域的庞大缺口

虽然政府掏出了数千亿令吉的援助金支援国人，依然还有许多人和企业受到大流行病的严重影响。为此，本集团在2020年7月通过独资子公司HS Priority Management私人有限公司，进军了租购融资和相关业务，辅助本集团当前的贷款业务，专注为商业汽车和工业器材与设备，提供租购融资。

马来西亚电子商务相当普遍，在政府祭出行动管制令后，物流服务的需求更是旺盛，尤其是最后一里路交付业务，为本地运输业带来巨大的增长；特别是为最后一里路交付服务供应商供应车辆的商家，以及对商用车的汽车贷款。



物流、船运港口和船坞、矿业、制造业和许多行业，都面临着现金流的问题，偏偏在当前的艰难时期，却是扩展车队和产能以应对需求日益暴增的必要时机。HS Priority能减轻此类业者的负担，以购入所需的车辆和重型机械，如罗里、卡车、起重机和叉车等。

受到现金流的影响，加上更严谨的贷款条件，许多贷款者无法取得正规银行所提供的各种融资便利。

因此，我们相信HS Priority能帮助填补当前融资市场的巨大缺口，放眼能支援所有领域的融资需求，为顾客提供弹性融资计划和具竞争力的利率。

## 我们的愿景

通过上述的计划，丰盛有信心能为本集团所有利益相关者创造良好且可持续的未来。我们承诺作为良好的企业，竭尽所能支持国家，不只是专注在医疗保健领域的单一部分，而是从端到端的所有领域层面，最大化效率。

在丰盛，我们的目标不仅仅是实现商业目标并遵守法律要求，同时也要为我们的社区和客户的社区，产生积极的社会效益。



HONG SENG CONSOLIDATED BERHAD  
(Formerly known as MSCM Holdings Berhad)  
[www.hongseng.com.my](http://www.hongseng.com.my)





# HONG SENG CONSOLIDATED Marches Ahead

The unprecedented COVID-19 pandemic has disrupted all countries and appears to be gaining traction. The solution or end to this global crisis does not seem near. Therefore, as the COVID-19 crisis multiplies, the goal of businesses must be to rebuild and plan for the longer term.

With that in mind, Hong Seng Consolidated Berhad ("Hong Seng") or formerly known as MSCM Holdings Berhad has recently entered and ventured into a series of strategic partnerships and corporate exercises to form a future whereby Hong Seng

would emerge stronger from the crisis as Albert Einstein's famous sayings goes "in the midst of every crisis, lies great opportunity".

By planning for the current pandemic, Hong Seng has significant plans to transform its business into three (3) main pillars which include gloves manufacturing, healthcare and medical supplies and services and the hire purchase services which are in high demand now and the foreseeable future.

Subsequent to the emergence of Hong Seng Assembly Sdn Bhd (HSASB) as the new major

shareholder of the Group, Hong Seng had on 19th October 2020 announced its proposed diversification into the relevant businesses as mentioned above and we are on track with our plans to evolve and grow the Group by reducing reliance on our existing core business of search, advertising and data.

We believe that currently, Hong Seng will be the only listed Group involved in or undertaking comprehensive end-to-end healthcare.

## Eyeing on USD18.8 Billion (And Growing) Global Glove Market

Based on the US-based Allied Market Research's report which estimated that the global disposable gloves market is expected to nearly triple to **USD18.8 billion** by 2027, Hong Seng has set its eyes on the opportunity from single-use medical gloves that have become increasingly difficult and costly to come by during this health crisis.

At the end of August 2020, Hong Seng through its wholly-owned subsidiary, Hong Seng Gloves Sdn Bhd (Hong Seng Gloves) has appointed its turnkey partner, Howelcare Industries Sdn Bhd to commission six (6) units of Nitrile Rubber (NBR) double former glove dipping production lines with utilities support system for our factory site located at Sungai Petani, Kedah.



Whilst we are currently ahead of schedule, the expected production capacity and output for each of the NBR double former glove dipping production line

is **241,920,000 pieces** per annum whilst the total expected production capacity and output for all 6 units of the NBR double former glove dipping production lines is **1,451,520,000 pieces** per annum. Hong Seng Gloves plans to increase up to a total of 16 production lines by early 2023 subjected to obtaining all necessary approvals to produce up to **3,670,720,000 pieces** per annum as demand and preorder requests from countries who are unable to procure from big players have been overwhelming.



Furthermore, Hong Seng Gloves have also secured its supply of raw material for NBR gloves and our total cost is estimated about **USD24.00** to **USD25.00** per carton of 1,000 pieces while the current average selling price is around **USD90.00** per carton.

Shareholders or any interested parties who wants to keep abreast with the latest progress of the glove manufacturing plant may do so on our Group's website at [www.hongseng.com.my](http://www.hongseng.com.my).



## Empowering Malaysians In The Fight Against Communicable Diseases And Beyond

Health is wealth. According to an online article published on the National Center for Biotechnology Information of United States titled "Learning opportunities from COVID-19 and future effects on health care system", the authors concluded that crisis like COVID-19 pandemic has also offered some unique opportunities for the healthcare sector. It has allowed us to revisit our healthcare delivery. Although, there has been severe disruption in healthcare delivery during this time globally, several positives have also come out of which include the effective use of telemedicine, importance of personal hygiene, and the importance of infection control.

Thus, Hong Seng intends to go full steam ahead in the healthcare industry and be at the forefront of the

Malaysian healthcare sector. Its wholly-owned subsidiary, HS Bio Supplies Sdn Bhd (HS Bio) is engaged in the business to provide pharmaceutical, medical and healthcare supplies such as e-medicine, medical consumables, bio supplies, medical equipment or devices, test-kits, vaccines, supplements, and other medical and healthcare related products as well as healthcare related services such as mobile testing facilities in addition to the supply chain management services for the healthcare industry.

The Group believes that HS Bio has promising prospects in the healthcare industry due to various factors. On 28th August 2020, HS Bio has invested and partnered with the Malaysian Medical Association (MMA) linked eMedAsia Sdn Bhd



(eMedAsia), which runs a medical digital platform that caters to thousands of private clinics in the nation to be latter's service provider for healthcare supply chain management services particularly the 3PL and 4PL fulfilments which includes warehousing, process, pick & pack, last mile delivery and purchase of medical and healthcare products. It is a milestone for HS Bio as it shows its seriousness and capabilities to penetrate the above listed markets as MMA is an official body for medical practitioners and clinics.

The strategic partnership between HS Bio and eMedAsia is part of a novel medical initiative to revolutionise the private healthcare sector. This may be a solution to the estimated USD 3.5 billion valued medical tourism industry in Malaysia by 2024 according to an insight by Malaysia Healthcare Travel Council.




Besides that, HS Bio is also currently in talks with several leading healthcare and pharmaceutical companies in China to be their distributor in Malaysia and the region. We are in the midst of helping these Chinese companies to get their products registered and approved by the relevant local authorities. The said products include amongst others, supplements which had been empirically proven to be effective in boosting immunity against SARS and Covid-19 and is much sought after globally at the moment, and real-time PCR Test Kits for detection of Covid-19 which was tested and used in Malaysia at the start of the Movement Control Order back in March 2020.

Once these are registered and approved, Hong Seng aims to make Covid-19 testing very efficient, affordable and accessible via our network of clinics within the eMedAsia community since it is possible that hotspots will require testing to be done before employees are allowed back to work. Again, our efforts will supplement and complement our government's efforts and strategy to combat the current wave.

Pursuant to positive discussions, HS Bio has also been invited to submit letters of intent to be the distributor of China developed vaccines to three (3) separate China parties. To undertake this endeavor of distributing the Covid-19 vaccines in Malaysia, we have tied up with one of the oldest and most established local pharmaceutical company, Royce Pharma through a consortium agreement. We would like to highlight to our shareholders and investors that to be accredited and licensed as a pharmaceutical company in Malaysia entails stringent steps such as lengthy regulatory applications. Further, to deal in vaccines, a distributor has to be properly equipped with the necessary infrastructure such as cold room warehousing, handling facilities and knowledge. These need time to construct and thereafter, be audited by the relevant innovators or manufacturers.

Therefore, a tie-up like our consortium agreement with Royce Pharma is the most practical and realistic approach compared to other non-pharmaceutical licensed companies claiming to distribute Covid-19 vaccines. This is also because Royce Pharma is able to carry out fill and finish processes required. In due course, we envision testing and vaccination to take place in private clinics for maximum reach and penetration and we will be best positioned to support our nation. We truly understand efforts by our Malaysian government in its participation in COVAX, which is costly yet unable to cover 100% of the Malaysian population and residents and this is where Hong Seng will be able to support our nation in her fight against Covid-19.



This is the reason why we believe we are at the forefront at this point of time as we have also written in to the relevant government ministry to indicate our readiness to support all governmental efforts to vaccinate our population once the vaccines are available.

Moreover, we are working closely with our strategic partner, Line Clear Express & Logistics Sdn Bhd to boost our supply chain management capability in providing 3PL and 4PL services to support our businesses such as eMedAsia's collaboration which includes mobile testing and vaccination trucks, glove fulfillment, vaccines and also other significant health products and services. All of these are just a small part of our vision to empower our nation in the fight against the pandemic.

Hong Seng is working very hard to delve into the healthcare sector and serve our nation. Our latest development is to be involved in supplying PCR Test Kits to government agencies especially to assist in the ongoing outbreak in Sabah. Discussions are also taking place to assist in building additional Test Labs for processing samples from the mass Covid-19 screenings. Hong Seng will make the relevant announcements when these come into fruition.

## Filling Up The Vital Vacuum In The Financing Sector

Although the government has poured in hundred of billions in subsidies to help the people, however there are still many people and businesses who are greatly affected by the pandemic. Therefore, in July 2020, our Group has ventured into the hire purchase and related business through our wholly-owned subsidiary, HS Priority Management Sdn Bhd (HS Priority) to complement our Group's existing moneylending business with focus on extending our hire purchase facilities for commercial vehicles as well as industrial machineries and equipment.

The pervasiveness of the e-commerce landscape in Malaysia, in particular after the MCO implemented by the Malaysian government, has led to flourishing demand for logistics services in particular the last-mile delivery. This has generated growth for the domestic transportation industry, particularly for those who supply vehicles to last-mile delivery service providers as well as demand for loans to automotive for commercial vehicles.

Many industry players such as logistics, shipping ports and yards, mining, manufacturing and many others are facing issues in their cash flows but there is a need and opportunity during this tough time to expand their vehicle fleet and production capacity to meet the surging demands and HS Priority is here help ease their burden to own the much needed vehicles and heavy machineries such as lorries, trucks, cranes, forklifts and etc.



At the moment, due to cashflow impact, many borrowers may not have access to the types of loan facilities made available by licensed banks and other financial institutions due to stringent lending requirements imposed.

Hence, we believe that HS Priority will be able to help fill the vital vacuum which exists in the current financing sector as we aims to provide financial support to all industries by providing our customers with flexible financing schemes and competitive interest rates.

## OUR VISION

With the above initiatives, Hong Seng believes that our Group will be able to create a good sustainable future together with our stakeholders. As we are committed to be a good corporate citizen, we are working hard to support the nation in our own capacity by not just focusing on a single segment of healthcare to make profits but end-to-end healthcare for maximum efficiency.

At Hong Seng, we take aim to not to only to deliver commercial objectives and meet legal requirements, but also have a positive social impact on our community and those communities of our customers.



**HONG SENG CONSOLIDATED BERHAD**  
(Formerly known as MSCM Holdings Berhad)  
[www.hongseng.com.my](http://www.hongseng.com.my)